Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans to invest USD 9.5 million in the establishment of a wholly-owned subsidiary in Germany that will provide Contract Research Organization (CRO) services. The new unit, temporarily named Jiuzhou Pharma Europe GmbH, is anticipated to be operational within two years.
The strategic move aims to reduce the service radius for international clients, enabling earlier involvement in the R&D processes of overseas customers. This initiative is expected to yield more customer resources and orders, while also bolstering the company’s domestic CDMO business. Furthermore, the establishment of this CRO platform in Germany will foster technical exchange and cooperation for Jiuzhou Pharmaceutical and attract top international talent to the company.- Flcube.com
